Shares of Medicus Pharma Ltd (NASDAQ:MDCX – Get Free Report) have been given a consensus recommendation of “Hold” by the five research firms that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $450.00.
A number of research firms have recently weighed in on MDCX. Brookline Capital Markets lowered Medicus Pharma from a “buy” rating to a “hold” rating in a research note on Wednesday, November 11th. Weiss Ratings upgraded Medicus Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 30th. Alliance Global Partners reaffirmed a “buy” rating on shares of Medicus Pharma in a research note on Monday, September 14th. Finally, Wall Street Zen downgraded Medicus Pharma from a “sell” rating to a “strong sell” rating in a research report on Sunday, November 8th.
Read Our Latest Stock Report on MDCX
Medicus Pharma Price Performance
Shares of MDCX opened at $1.52 on Wednesday. The firm has a market cap of $2.92 million, a P/E ratio of -0.02 and a beta of 0.80. The stock has a 50 day simple moving average of $4.84 and a two-hundred day simple moving average of $19.55. Medicus Pharma has a 1 year low of $1.50 and a 1 year high of $115.50.
Medicus Pharma (NASDAQ:MDCX – Get Free Report) last posted its quarterly earnings results on Friday, November 6th. The company reported ($11.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($8.50) by ($3.14). On average, equities analysts anticipate that Medicus Pharma will post -33.50 earnings per share for the current year.
Hedge Funds Weigh In On Medicus Pharma
A number of hedge funds have recently modified their holdings of MDCX. Private Advisor Group LLC grew its position in shares of Medicus Pharma by 36.8% in the 1st quarter. Private Advisor Group LLC now owns 240,055 shares of the company’s stock worth $110,000 after buying an additional 64,560 shares during the last quarter. Sterling Investment Advisors Ltd. purchased a new position in shares of Medicus Pharma during the second quarter valued at approximately $45,000. Finally, Interchange Capital Partners LLC lifted its stake in Medicus Pharma by 33.9% in the third quarter. Interchange Capital Partners LLC now owns 2,124,910 shares of the company’s stock worth $343,000 after acquiring an additional 538,039 shares during the period.
Medicus Pharma Company Profile
Medicus Pharma Ltd. is a clinical-stage biopharmaceutical company developing treatments for dermatological and oncological conditions. Its lead program, SkinJect, is an investigational intradermal drug-delivery approach being developed for basal cell carcinoma, a common form of skin cancer. SkinJect uses a dissolving microneedle array designed to deliver medication into affected skin. The company’s work is focused on advancing this program through clinical development; it is not an established commercial treatment.
Further Reading
- Five stocks we like better than Medicus Pharma
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Medicus Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicus Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
